Physician profile
Mclean Sheperd
NPI 1689617128
$10,115.63
in general payments reported to CMS, 2019-2025
32 companies · $799 in 2025
The $799 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $931 · 2021: $4,132 · 2022: $1,230 · 2023: $806 · 2024: $1,036 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,570 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,569.93 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,114.60 | 2019-2022 | |
| Abbvie INC. | $939.39 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Pfizer INC. | $548.43 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $535.11 | 2019-2025 | Ilumya, Winlevi |
| Novartis Pharmaceuticals Corporation | $411.76 | 2019-2025 | |
| Janssen Biotech, INC. | $376.25 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Almirall LLC | $357.30 | 2019-2025 | Klisyri, Seysara |
| Genzyme Corporation | $339.20 | 2021-2025 | |
| Amgen INC. | $320.72 | 2020-2025 | Otezla |
| Galderma Laboratories, L.P. | $311.83 | 2019-2025 | Aklief, Nemluvio |
| Leo Pharma INC. | $295.89 | 2019-2024 | Adbry |
| Regeneron Healthcare Solutions, INC. | $249.26 | 2019-2023 | Libtayo, Dupixent |
| Incyte Corporation | $174.50 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $166.58 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $160.18 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $123.05 | 2022-2024 | Vtama |
| Lilly USA, LLC | $85.17 | 2019-2020 | |
| Merz North America, INC. | $67.52 | 2025 | |
| Prugen, INC. Pharmaceuticals | $60.92 | 2019-2020 | |
| Celgene Corporation | $60.55 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $58.25 | 2022-2023 | Sotyktu |
| Dermira, INC. | $57.16 | 2019-2020 | |
| Ucb, INC. | $55.85 | 2019-2023 | Cimzia |
| Mayne Pharma Commercial LLC | $53.28 | 2019-2021 | |
| Genentech USA, INC. | $36.07 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.61 | 2024 | Spevigo |
| Epi Health, LLC | $26.53 | 2020 | |
| Journey Medical Corporation | $26.10 | 2022 | |
| Organon LLC | $22.67 | 2025 | Vtama |
| Medtronic Vascular, INC. | $17.66 | 2020 | |
| Mylan Pharmaceuticals INC. | $15.77 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $13.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mclean Sheperd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.